DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

ARGX·Argenx SE American Depositary Shares

$.
-. (-.%)
After Hours
High
$939.84
Open
$935.00
Market Cap
49.86B
52W High
$833.60
Low
$910.19
P. Close
$918.92
P/E
25.25
52W Low
$511.60
Fwd P/E
25.05
DailyIQ Est.
$1140.81
Technical Score (1D)
91
BUY
News Sentiment
86
BULLISH
RBC Capital Markets noted that Argenx’s Q2 revenue beat was driven by organic demand in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and flagged a potential ocular MG label expansion that could lift sales. The upbeat earnings suggest the company’s pipeline is gaining traction, which could support near‑term upside as the market anticipates further data releases. RBC also raised its price target to $1,025, reflecting confidence in the company’s growth prospects and the favorable payer dynamics that have eased adoption barriers. Oppenheimer followed suit, lifting its target to $1,037 while maintaining an Outperform rating, underscoring a bullish view on the pipeline. Other analysts, including Guggenheim, have also increased their targets, while Citizens lowered its target to $932 but kept an Outperform rating, indicating some short‑term caution amid ongoing clinical developments. The company’s recent FDA approvals for Vyvgart and its subcutaneous Hytrulo formulation expand treatment options for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, reinforcing the revenue base. Upcoming myositis data is expected to be a key driver for the next trading days, as it could confirm the efficacy of the company’s therapies in a broader patient population. Investors should also monitor the potential ocular MG label expansion and any regulatory milestones that could validate the higher valuation. Finally, the company’s cash generation and operational leverage improvements suggest it can sustain growth without immediate financing pressure, which may keep the stock resilient in the short term.
Earnings Summary
argenx SE is a commercial‑stage biotechnology company that develops therapies for autoimmune diseases, with its flagship product VYGART approved for generalized myasthenia gravis and a subcutaneous formulation available. Operating in the healthcare sector, the company’s pipeline includes investigational agents such as efgartigimod for ocular gMG and immune thrombocytopenia, positioning it for diversified revenue streams. In Q4 2024 the firm reported earnings per share of $0.71, falling short of the consensus estimate of $1.70, while revenue of $724.4 million represented a modest decline from the prior year’s comparable period; the forthcoming quarters of 2026 carry higher consensus expectations with EPS estimates rising to $6.94 in Q2 and $7.43 in Q3 and revenue estimates climbing to $1.57 billion and $1.59 billion respectively, indicating a pronounced upward trajectory in both earnings and top line. Historically, the company has posted a 60 % year‑over‑year jump in product net sales in Q2 2026, marking its 18th consecutive quarter of revenue growth, and the FDA approval of VYVGART for seronegative generalized myasthenia gravis expands its addressable market; however, the limited availability of actual results beyond Q4 2024 prevents a definitive assessment of year‑over‑year trends, though the available estimates suggest a strong acceleration in revenue expectations. Recent developments include the 60 % sales jump to $1.52 billion in Q2 2026 driven by the expanded labeling, the upcoming readouts for myositis and multifocal motor neuropathy in Q3 and Q4, and a collaboration with Chai Discovery that could accelerate pipeline progress; analysts have adjusted price targets in response to these moves, reflecting uncertainty around the timing of additional approvals. Investors should watch the Q3 2026 earnings call for guidance on revenue, operating profit, and the outcomes of the planned readouts, as well as any updates on payer coverage or reimbursement policies that could influence the commercial uptake of VYVGART and empasiprubart.

EPS

EstBeatMiss
$-0.22$1.80$3.83$5.85$7.88Q4'24Q2'26
QtrEstActual+/−
Q2'26$6.94 - -
Q4'24$1.70$0.71-58.0%

Revenue

EstBeatMiss
$598M$872M$1.1B$1.4B$1.7BQ4'24Q2'26
QtrEstActual+/−
Q2'26$1.6B - -
Q4'24 - $724M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ARGX Stock Snapshot

ARGX is currently trading at $918.22, giving Argenx SE American Depositary Shares a market cap of 49.86B and a P/E ratio of 25.3. Today's range spans $910.19–$939.84, with shares opening at $935.00 and moving down $0.70 (0.1%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 86/100.

Over the past year ARGX has traded between $511.60 and $833.60 - the current price is +79.5% off the 52-week low and +10.2% from the high. 27 analysts cover the stock with a Buy consensus and a mean 12-month target of $1079.39 (range $770.00–$1291.00), implying upside of +17.6%.

The BUY technical setup for ARGX (91/100) is worth attention in the context of the broader Healthcare sector. At $918.22 (near 52-week highs), with 49.86B in capitalization and bullish sentiment at 86/100 The current P/E ratio stands at 25.3., this large-cap name sits at the intersection where momentum strategies and fundamental growth investors both find something to like. Annual range: $511.60–$833.60.

The combination of a BUY signal (91/100) and bullish news sentiment (86/100) puts ARGX on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 49.86B in Healthcare market cap without immediately moving the stock. At $918.22 (near 52-week highs in the $511.60–$833.60 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.